FDA Approves Awiqli® for Children 10 Years and Older with Type 2 Diabetes

The FDA has approved Awiqli® (insulin icodec-abae) 700 units/mL for children aged 10 years and older with type 2 diabetes, allowing for a once-weekly injection instead of daily doses. Novo Nordisk aims to enhance individualized care and reduce administration barriers for young patients and caregivers. This approval addresses the rising public health challenge of type 2 diabetes among youth.